Grifols SA
OZTA
Company Profile
Business description
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Contact
Avinguda de la Generalitat, 152
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935712200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,737
Stocks News & Analysis
stocks
Vote in favour of merger for undervalued ASX share
We recommend shareholders vote in favor of its proposed merger.
stocks
Are investors missing the boat on this future ASX leader?
The market is underestimating the clear path to profitability.
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,557.40 | 11.70 | -0.14% |
| CAC 40 | 7,711.80 | 77.06 | 1.01% |
| DAX 40 | 20,901.17 | 245.78 | 1.19% |
| Dow JONES (US) | 43,595.24 | 442.11 | 1.02% |
| FTSE 100 | 8,508.18 | 116.28 | 1.39% |
| HKSE | 19,584.06 | 61.17 | 0.31% |
| NASDAQ | 19,636.38 | 298.09 | 1.54% |
| Nikkei 225 | 38,451.46 | 121.14 | -0.31% |
| NZX 50 Index | 13,130.43 | 129.76 | 1.00% |
| S&P 500 | 6,004.12 | 66.78 | 1.12% |
| S&P/ASX 200 | 8,310.40 | 16.60 | -0.20% |
| SSE Composite Index | 3,241.82 | 5.79 | 0.18% |